Clene reports FY2022 net loss of $29.9M; highlights positive clinical data in ALS and MS

Clene Inc.

Net loss $29.9M ($0.46/share) vs $9.7M ($0.16) prior year; cash $23.3M, runway into Q3 2023.
HEALEY ALS trial: CNM-Au8 associated with 74% lower risk of clinical worsening at 6 months; 98% reduced risk of death/permanent ventilation.
RESCUE-ALS OLE: significant ALSFRS-R preservation from randomization to 48 weeks (p=0.0159).
VISIONARY-MS trial: significant improvements in visual evoked potential and MRI measures supporting neuroprotection.
Plans to meet FDA in Q3 2023 for end-of-Phase 2 meetings for ALS and MS; secured $25M equity facility with Lincoln Park.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Clene Inc. reported financial results for full year ended December 31, 2022.

Period: full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 13, 2023, Clene Inc. (the “Company”) issued a press release announcing its full year operating and financial results for its year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-006270

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.